Intravenous immunoglobulin (IVIG) works against autoimmune disease through several overlapping mechanisms: it blocks the receptors immune cells use to attack your own tissues, intercepts and neutralizes the harmful antibodies driving the disease, dials down inflammation by quieting overactive immune signaling, and boosts the population of immune cells whose job is to keep the rest of the immune system in check. No single mechanism explains the full effect. Instead, IVIG acts on multiple parts of the immune system simultaneously, which is why it’s effective across such a wide range of autoimmune conditions.
Each batch is manufactured from pooled plasma donated by roughly 10,000 healthy individuals, resulting in a product that is 95 to 98 percent pure IgG antibodies. That enormous donor pool is key: it means the final product contains an extremely diverse collection of antibodies, giving it the range to interact with many different targets in your immune system at once.
Blocking the Receptors That Drive Cell Destruction
In many autoimmune diseases, your immune system tags your own cells with antibodies. Immune cells called macrophages then latch onto these tagged cells through surface receptors known as Fc receptors, and destroy them. This is the core process behind conditions like immune thrombocytopenia (ITP), where platelets are destroyed, and autoimmune hemolytic anemia, where red blood cells are the target.
IVIG floods the system with a massive dose of IgG antibodies that compete for those same Fc receptors. When enough of the receptors are occupied by the infused antibodies, macrophages can no longer efficiently grab and destroy the tagged cells. Think of it like filling every parking spot in a lot: the destructive antibodies still circulate, but they can’t “park” and do their damage. This receptor saturation is one of the fastest-acting mechanisms of IVIG, which is why platelet counts in ITP can rise within days of an infusion.
IVIG also shortens the lifespan of those harmful autoantibodies. Your body recycles IgG antibodies through a receptor called FcRn, which rescues them from being broken down. When IVIG raises the total IgG concentration dramatically, this recycling system becomes overwhelmed. Autoantibodies get degraded faster because there’s too much IgG competing for the limited recycling capacity. The net result is a measurable drop in the concentration of the disease-causing antibodies.
Neutralizing Autoantibodies Directly
Because IVIG is sourced from thousands of donors, it contains antibodies that recognize an enormous variety of molecular shapes, including shapes found on other antibodies. Some of these recognize the unique binding regions (called idiotypes) on disease-driving autoantibodies and physically block them. This is called anti-idiotypic neutralization: essentially, antibodies that target other antibodies.
This has been demonstrated in lupus, where anti-idiotypic antibodies in IVIG bind to the autoantibodies that attack DNA, reducing their levels and suppressing disease activity in animal models. The same principle applies across other autoimmune conditions. By neutralizing autoantibodies and interacting with receptors on the B cells that produce them, IVIG can suppress the autoreactive B cell populations responsible for ongoing antibody production. This means the benefit isn’t purely about mopping up existing autoantibodies; it also helps slow the creation of new ones.
Shutting Down Complement-Mediated Damage
The complement system is a cascade of proteins that amplifies immune attacks. In autoimmune disease, complement activation on your own tissues can punch holes in cell membranes through a structure called the membrane attack complex, leading to direct cell death. This mechanism is especially relevant in conditions affecting nerves and muscles, such as Guillain-Barré syndrome and myasthenia gravis.
IVIG interrupts this cascade at a critical step. It binds to complement fragments called C3b and C4b, preventing them from assembling into the later-stage complexes needed to form the membrane attack complex. Without that final assembly, cell lysis doesn’t occur. IVIG also saturates complement receptors on macrophages, which prevents immune complexes coated in complement from being efficiently cleared through inflammatory pathways. Research published in Neurology confirmed that serum drawn from patients after IVIG treatment actively inhibited the uptake of these complement fragments in laboratory testing, providing direct evidence that this mechanism operates in treated patients.
Expanding Regulatory T Cells
Your immune system has built-in brakes: regulatory T cells (Tregs) that suppress overactive immune responses. In autoimmune disease, Treg populations are often reduced or dysfunctional, leaving inflammatory processes unchecked. IVIG expands the Treg population through a surprisingly indirect route.
Research published in Blood showed that IVIG interacts with dendritic cells, the immune cells that coordinate immune responses, and triggers them to produce a signaling molecule called prostaglandin E2 through a specific enzyme pathway. This signaling molecule then drives the expansion of Tregs. When researchers blocked this enzyme pathway, IVIG lost its ability to expand Tregs both in the lab and in living animals, and its protective effect against autoimmune disease was significantly diminished. Interestingly, this particular mechanism is driven by the antibody-binding portion of the IgG molecules, not the Fc tail involved in receptor blockade, which means different parts of the same molecule are responsible for different therapeutic effects.
The expanded Treg population helps restore immune balance more broadly, tamping down the inflammatory T cell responses that perpetuate tissue damage in conditions ranging from inflammatory myopathies to vasculitis.
What Treatment Looks Like in Practice
For autoimmune conditions, IVIG is typically given at high doses of 1 to 2 grams per kilogram of body weight. For a 70-kilogram person, that translates to roughly 70 to 140 grams of immunoglobulin per treatment cycle. This is substantially higher than doses used for immune deficiency, where the goal is simply to replace missing antibodies rather than to suppress an overactive immune system.
Infusions are delivered through an IV line, and a single treatment cycle may be completed in one session or spread across one to five consecutive days depending on the condition and how well you tolerate the infusion. Many autoimmune conditions require repeat cycles, often monthly, with the frequency and duration tailored to how you respond. Some people receive IVIG as a short-term bridge while other treatments take effect; others depend on it as ongoing maintenance therapy for months or years.
Common Side Effects
IVIG is generally well tolerated, but side effects are common enough that you should know what to expect. In a systematic review pooling data from 688 patients, about 39 percent experienced at least one adverse event. Headache is by far the most frequent, accounting for roughly a quarter of all reported side effects, followed by fever at about 18 percent. Nausea and fatigue each occur in around 4 to 5 percent of patients.
Many side effects are tied to the infusion itself, occurring during or shortly after treatment. About 13 percent of individual infusions are accompanied by some reaction, most commonly headache and fever. Delayed reactions, appearing hours to days after the infusion, are actually more common than immediate ones. In one study, delayed reactions occurred after about 21 percent of infusions compared to just 3.5 percent for immediate reactions, with headache, fatigue, and abdominal pain being the most frequent delayed complaints. Slowing the infusion rate or premedicating with acetaminophen and antihistamines often reduces or prevents these reactions.
Serious Risks to Be Aware Of
All IVIG products carry FDA boxed warnings for two serious risks: blood clots (thrombosis) and kidney damage. The thrombosis risk applies to intravenous, subcutaneous, and intramuscular immunoglobulin products alike. People with pre-existing risk factors for clotting, such as a history of blood clots, heart disease, prolonged immobility, or use of estrogen-containing medications, face higher risk. Kidney problems are more common in patients with pre-existing renal issues and are associated with certain stabilizers used in some IVIG formulations.
These serious complications are uncommon relative to the millions of infusions administered each year, but they’re the reason IVIG is reserved for conditions where the benefit clearly outweighs the risk, and why infusion centers monitor patients during and after treatment.